Detalhe da pesquisa
1.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
N Engl J Med
; 378(4): 321-330, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365294
2.
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
BMC Neurol
; 18(1): 188, 2018 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413151
3.
Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population.
J Affect Disord
; 321: 272-278, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36280197
4.
Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study.
Curr Med Res Opin
; 37(11): 1945-1955, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34429000
5.
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Alzheimers Dement (N Y)
; 7(1): e12123, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33614894
6.
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
JAMA Neurol
; 77(2): 199-209, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31764959
7.
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies.
Patient Prefer Adherence
; 12: 1785-1795, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30271122
8.
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Neurology
; 91(24): e2211-e2221, 2018 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446596
9.
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
J Alzheimers Dis
; 47(1): 205-14, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26402769